Quince Therapeutics (NASDAQ:QNCX) Posts Earnings Results, Misses Estimates By $0.09 EPS

Quince Therapeutics (NASDAQ:QNCX) issued its quarterly earnings results on Monday. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.09), Zacks reports. The company had revenue of $0.17 million for the quarter.

Quince Therapeutics Price Performance

Shares of QNCX stock opened at $1.40 on Tuesday. The firm’s 50 day moving average price is $1.49 and its two-hundred day moving average price is $1.44. The company has a debt-to-equity ratio of 0.33, a quick ratio of 9.53 and a current ratio of 9.53. Quince Therapeutics has a 52-week low of $0.51 and a 52-week high of $2.45. The stock has a market cap of $61.60 million, a PE ratio of -1.13 and a beta of 0.71.

Analyst Upgrades and Downgrades

QNCX has been the subject of a number of research analyst reports. Oppenheimer initiated coverage on shares of Quince Therapeutics in a research note on Monday. They issued an “outperform” rating and a $10.00 target price for the company. D. Boral Capital reduced their price objective on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday. Finally, Brookline Capital Management started coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective on the stock. Five investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $8.00.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.